Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings.

"data s1."

"Declaration of interests A.J.D. reports grants from Braeburn/Camurus AB, to conduct clinical studies with buprenorphine products and travel support to Hunter New England Local Health District, which employs A.J.D. He is an honorary investigator on an Indivior‐funded study of buprenorphine products and has served on an advisory board for Mundipharma. P.S.H. reports grants from Braeburn/Camurus AB, to conduct clinical studies with buprenorphine products and has served on advisory boards for Lundbeck, Indivior, AbbVie and Gilead. N.L. reports grants from Braeburn and Camurus AB to conduct sponsored and investigator‐led clinical studies with CAM2038. N.L. served on Advisory Boards for Mundipharma, Indivior and Chiesi Pharmaceuticals. M.C. was employed by the NSW Ministry of Health, sponsors of the study. All other authors declare no competing interests."

"We wish to thank all the JHFMHN Drug and Alcohol management, clinical, pharmacy and frontline staff, as well as CSNSW custodial staff and management, who supported the trial. We are grateful to members of our Aboriginal Advisory Group and Data Safety Monitoring Board for their time, expertise and contributions. We give a special thanks and acknowledge Monique Hourn for trial monitoring, and researcher officers Sophia Little, Kerryn Butler, Jeff Stormer and Fatema Sake who conducted all research interviews. We would also acknowledge Wedyan Meshreky's contribution to study development and Erin Nolan for data analysis. Finally, we gratefully acknowledge study participants, without whom this work would not have been possible."